ROR2 and non-small cell lung carcinoma: ROR2 expression has been described in non-small cell lung cancer (NSCLC), melanoma, squamous cell carcinoma of head and neck (SCCHN), osteosarcoma, neuroblastoma and renal cell carcinoma [22], and CAR T-cells with anti-tumour activity have been generated against this target [23].